Loading... (0%)
About liver disease

Publications scientifiques

Elafibranor, an Agonist of the Peroxisome Proliferator-activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
Ratziu V, Harrison S, Francque S, Bedossa P, Lehert P, Serfaty L, Romero-Gomez M, Boursier J, Abdelmalek M, Caldwell S, Drenth J, Anstee Q, Hum D, Hanf R, Roudot A, Megnien S, Staels B, Sanyal A; GOLDEN505 investigator study group, Gastroenterology, 2016 Feb 11. [Epub ahead of print]

GFT505 for the treatment of nonalcoholic steatohepatitis and type 2 diabetes
Cariou B, Staels B., Expert Opin Investig Drugs. 2014 Oct; 23(10): 1441-8

The dual peroxisome proliferator-activated receptor alpha/delta agonist GFT505 exerts anti-diabetic effects in db/db mice without peroxisome proliferator-activated receptor gamma-associated adverse cardiac effects
Hanf R, Millatt LJ, Cariou B, Noel B, Rigou G, Delataille P, Daix V, Hum DW, Staels B. Diab Vasc Dis Res. 2014 Sep 11. [Epub ahead of print]

Pan-PPAR Modulation Effectively Protects APP/PS1 Mice from Amyloid Deposition and Cognitive Deficits
Kummer MP, Schwarzenberger R, Sayah-Jeanne S, Dubernet M, Walczak R, Hum DW, Schwartz S, Axt D, Heneka MT, Mol Neurobiol, 2014 May, 17

Nuclear control of inflammation and fibrosis in NASH: Therapeutic potential of dual pparα/δ agonism
Quintero P, Arrese M. Departamento de Gastroenterología, Pontificia Universidad Católica de Chile, Santiago, Chile. Hepatology. 2013 Jun 20. doi: 10.1002/hep.26582. (Editorial sur GFT505 par auteurs indépendants)

Hepato-protective effects of the dual PPARalpha/delta agonist GFT505 in rodent models of NAFLD/NASH
B Staels, A Rubenstrunk, B Noel, G Rigou, P Delataille, LJ Millatt, M Baron, A Lucas, A Tailleux, DW Hum, V Ratziu, B Cariou and R Hanf, Hepatology, 2013

Dual Peroxisome Proliferator-Activated Receptor alpha/delta Agonist GFT505 Improves Hepatic and Peripheral Insulin Sensitivity in Abdominally Obese Subjects
B Cariou, R Hanf, S Lambert-Porcheron, Y Zair, V Sauvinet, B Noel, L Flet, H Vidal, B Staels and M Laville, Diabetes Care, 2013

Identification of New Nonsteroidal RORα Ligands; Related Structure–Activity Relationships and Docking Studies
M Dubernet, N Duguet, L Colliandre, C Berini, S Helleboid, M Bourotte, M Daillet, L Maingot, S Daix, J-F Delhomel, L Morin-Allory, S Routier and R Walczak, ACS Medicinal Chemistry Letters, 2013, 4 504-508

Le GFT505, un co-agoniste PPARα/δ, améliore la sensibilité périphérique et hépatique à l’insuline chez des patients obèses insulinorésistants
B Cariou, R Hanf, S Ambert-Porcheron, Y Zaïr, L Flet, H Vidal, B Staels and M Laville, Diabetes & Metabolism, 2013, 39, Supplement 1 A11

Roles of PPARs in NAFLD: potential therapeutic targets
A Tailleux, K Wouters and B Staels, Biochim Biophys Acta, 2012, 1821 809-18

Anti-inflammatory drug evaluation in ApoE-/- mice by ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging
M Sigovan, E Kaye, E Lancelot, C Corot, N Provost, Z Majd, M Breisse and E Canet-Soulas, Invest Radiol, 2012, 47 546-52

Does endoplasmic reticulum stress participate in APD-induced hepatic metabolic dysregulation ?
E Lauressergues, E Bert, P Duriez, D Hum, Z Majd, B Staels and D Cussac, Neuropharmacology, 2012, 62 784-96

Activation of intestinal peroxisome proliferator-activated receptor-alpha increases high-density lipoprotein production
S Colin, O Briand, V Touche, K Wouters, M Baron, F Pattou, R Hanf, A Tailleux, G Chinetti, B Staels and S Lestavel, Eur Heart J, 2012

The new dual PPARα/δ agonist GFT505 improves hepatic insulin resistance and decreases serum liver enzymes in abdominally obese patients
B Cariou, R Hanf, S Lambert-Porcheron, Y Zaïr, L Flet, B Staels and M Laville, Journal of Hepatology, 2012, 56, Supplement 2 S554-S555

Subcutaneous adipose tissue remodeling during the initial phase of weight gain induced by overfeeding in humans
M Alligier, E Meugnier, C Debard, S Lambert-Porcheron, E Chanseaume, M Sothier, E Loizon, AA Hssain, J Brozek, JY Scoazec, B Morio, H Vidal and M Laville, J Clin Endocrinol Metab, 2012, 97 E183-92

Present and future challenges in Type 2 diabetes
L Millatt, R Hanf and D Hum, Drug Discovery World, 2011, Summer 2011 9-15

Overweight induced by chronic risperidone exposure is correlated with overexpression of the SREBP-1c and FAS genes in mouse liver
E Lauressergues, F Martin, A Helleboid, E Bouchaert, D Cussac, R Bordet, D Hum, G Luc, Z Majd, B Staels and P Duriez, Naunyn Schmiedebergs Arch Pharmacol, 2011, 383 423-36

GFT505, a dual PPARα/δ agonist has beneficial effects in animal models of NAFLD/NASH through PPARα-dependent and independent mechanisms – Abstracts of the 47th Annual Meeting of the European Association for the Study of Diabetes. September 16, 2011. Lisbon, Portugal
R Hanf, A Rubenstrunck, M Baron, R Walczak, A Tailleux, D Hum and B Staels, Diabetologia, 2011, 54 Suppl 1 S510

Effects of the new dual PPAR alpha/delta agonist GFT505 on lipid and glucose homeostasis in abdominally obese patients with combined dyslipidemia or impaired glucose metabolism
B Cariou, Y Zair, B Staels and E Bruckert, Diabetes Care, 2011, 34 2008-14

Le GFT505, premier co-agoniste PPAR α/δ, a une double action favorable sur les paramètres lipidiques et glucidiques chez les sujets pré-diabétiques
B Cariou, R Hanf, E Bruckert, R Darteil, DW Hum and B Staels, Diabetes & Metabolism, 2011, 37 A19-A20

PPARalpha activation differently affects microparticle content in atherosclerotic lesions and liver of a mouse model of atherosclerosis and NASH
M Baron, AS Leroyer, Z Majd, F Lalloyer, E Vallez, K Bantubungi, G Chinetti-Gbaguidi, P Delerive, CM Boulanger, B Staels and A Tailleux, Atherosclerosis, 2011, 218 69-76

Assessment of age modulated vascular inflammation in ApoE-/- mice by USPIO-enhanced magnetic resonance imaging
M Sigovan, A Bessaad, H Alsaid, E Lancelot, C Corot, B Neyran, N Provost, Z Majd, M Breisse and E Canet-Soulas, Invest Radiol, 2010, 45 702-7

Antipsychotic drug action on SREBPs-related lipogenesis and cholesterogenesis in primary rat hepatocytes
E Lauressergues, B Staels, K Valeille, Z Majd, DW Hum, P Duriez and D Cussac, Naunyn Schmiedebergs Arch Pharmacol, 2010, 381 427-39

Meeting : ADA 70th Scientific Sessions (2010) – GFT505 Efficacy and Safety in Healthy Volunteers and Patients Suffering from Atherogenic Dyslipidemia
R Hanf, R Darteil, DW Hum and B Staels, Diabetes, 2010, 59 677-P

Meeting : ADA 70th Scientific Sessions (2010) – GFT505 Improves Glucose and Lipid Homeostasis in Patients with Impaired Fasting Glucose and Impaired Glucose Tolerance
R Hanf, E Bruckert, B Cariou, R Darteil, D Hum and B Staels, Diabetes, 2010, 59 12-LB

M1-activated macrophages migration, a marker of aortic atheroma progression: a preclinical MRI study in mice
A Bessaad, M Sigovan, H Alsaid, G De Souza, N Provost, Z Majd, C Menager, J Honnorat, F Lagarde, N Nighoghossian, S Nataf and E Canet-Soulas, Invest Radiol, 2010, 45 262-9

adipiscing odio ut in sem, id,